Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

This study tests whether continuing targeted therapy (encorafenib + binimetinib) after surgery for stage III or IV melanoma with a specific BRAF mutation leads to better outcomes, especially when the tumor showed a good response to pre-surgery treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of melanoma - Your melanoma has a BRAF V600 mutation (tested in a certified lab) - Your cancer is stage III (B, C, or D) or stage IV - Your general health status is adequate (ECOG 0–2) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - Your melanoma does not have a BRAF V600 mutation - You have active brain metastases that are not stable - You have a history of significant heart problems - You have previously received BRAF or MEK inhibitor therapy Talk to your doctor to see if this trial is right for you.